Language selection

Search

Patent 2476824 Summary

Third-party information liability

Some of the information on this Web page has been provided by external sources. The Government of Canada is not responsible for the accuracy, reliability or currency of the information supplied by external sources. Users wishing to rely upon this information should consult directly with the source of the information. Content provided by external sources is not subject to official languages, privacy and accessibility requirements.

Claims and Abstract availability

Any discrepancies in the text and image of the Claims and Abstract are due to differing posting times. Text of the Claims and Abstract are posted:

  • At the time the application is open to public inspection;
  • At the time of issue of the patent (grant).
(12) Patent Application: (11) CA 2476824
(54) English Title: IODINATION OF 4-FLUORO-BENZALDEHYDE
(54) French Title: IODATION DE 4-FLUORO-BENZALDEHYDE
Status: Dead
Bibliographic Data
(51) International Patent Classification (IPC):
  • C07C 45/63 (2006.01)
  • C07C 47/55 (2006.01)
(72) Inventors :
  • WITTENBERGER, STEVEN J. (United States of America)
  • CHANG, SOU-JEN (United States of America)
  • WAYNE, GREGORY S. (United States of America)
(73) Owners :
  • ABBOTT LABORATORIES (United States of America)
(71) Applicants :
  • ABBOTT LABORATORIES (United States of America)
(74) Agent: TORYS LLP
(74) Associate agent:
(45) Issued:
(86) PCT Filing Date: 2003-02-03
(87) Open to Public Inspection: 2003-08-28
Availability of licence: N/A
(25) Language of filing: English

Patent Cooperation Treaty (PCT): Yes
(86) PCT Filing Number: PCT/US2003/003082
(87) International Publication Number: WO2003/070678
(85) National Entry: 2004-08-19

(30) Application Priority Data:
Application No. Country/Territory Date
10/078,617 United States of America 2002-02-19

Abstracts

English Abstract




The present invention relates to an improved process for iodinating a
substituted benzaldehyde


French Abstract

L'invention concerne un procédé amélioré d'iodation d'un benzaldéhyde substitué.

Claims

Note: Claims are shown in the official language in which they were submitted.



We claim.
1. A process for producing 4-fluoro-3-iodobenzaldehyde by combining 4-
fluorobenzaldehyde, N-iodosuccinimide in an acid medium.
2. A process of claim 1 wherein said acid is an organic acid.
3. A process of claim 2 wherein said organic acid is trifluoromethanesulfonic
acid.
4. A process of claim 1 wherein said acid is an inorganic acid.
5. A process of claim 4 wherein said inorganic acid is selected from the group
consisting of
nitric, sulfuric, and hydrochloric acid.
6. A process of claim 1 wherein said acid is an inorganic acid in combination
with acetic
acid.
7. A process of claim 4 herein said inorganic acid/acetic acid combination is
in a 1:1 ratio.

Description

Note: Descriptions are shown in the official language in which they were submitted.




CA 02476824 2004-08-19
WO 03/070678 PCT/US03/03082
S IODINATION OF 4-FLUORO-BENZALDEHYDE
Background of the Invention
Potassium channels play an important role in regulating cell membrane
excitability.
When the potassium channels open, changes in the electrical potential across
the cell membrane
occur and result in a more polarized state. A number of diseases or conditions
may be treated
with therapeutic agents that open potassium channels; see for example (K.
Lawson, Pharmacol.
Ther., v. 70, pp. 39-63 (1996)); (D.R. Gehlert et al., Prog. Neuro-
Psychopharmacol & Biol.
Psychiat., v. 18, pp. 1093-1102 (1994)); (M. Gopalakrishnan et al., Drug
Development Research,
v. 28, pp. 95-127 (1993)); (J.E. Freedman et al., The Neuroscientist, v. 2,
pp. 145-152 (1996));
(D. E. Nurse et al., Br. J. Urol., v. 68 pp. 27-31 (1991)); (B. B. Howe et
al., J. Pharmacol. Exp.
Ther., v. 274 pp. 884-890 (1995)); (D. Spanswick et al., Nature, v. 390 pp.
521-25 (December 4,
1997)); (Dompeling Vasa. Supplementum (1992) 3434); (W09932495); (Grover, J
Mol Cell
Cardiol. (2000) 32, 677); and (Buchheit, Pulmonary Pharmacology & Therapeutics
(1999) 12,
103). Such diseases or conditions include asthma, epilepsy, male sexual
dysfunction, female
sexual dysfunction, pain, bladder overactivity, stroke, diseases associated
with decreased skeletal
blood flow such as Raynaud's phenomenon and intermittent claudication, eating
disorders,
functional bowel disorders, neurodegeneration, benign prostatic hyperplasia
(BPH),
dysmenorrhea, premature labor, alopecia, cardioprotection, coronary artery
disease, angina,
ischemia, and incontinence.
4-fluoro-3-iodo-benzaldehyde was previously synthesized in five steps as shown
in
Scheme 1. In summary, 4-fluorobenzoic acid (1) is converted to 4-fluoro-3-
nitrobenzoic acid (2)
which is then reduced to the corresponding amine (3). Further reduction
results in the alcohol
(4) and subsequent iodination (5) and oxidation ultimately leads to the
iodinated benzaldehyde
(6).



CA 02476824 2004-08-19
WO 03/070678 PCT/US03/03082
F F F
F
NOp ~ NHy ~ NHz
COZH COyH COpH
HO 4
2
F F
F
NHz ~ I I
HO 4 HO 5 CHO 6
Another process for producing 4-fluoro-3-iodobenzaldehyde is shown in Scheme
II.
There are disadvantages to this process as 4-fluoro-3-bromo-benzaldehyde is
relatively
expensive as a starting material and the process requires low temperature
conditions.
Scheme II
F
F F
Br ~ Br ~ I
CHO ~ 8 6
CHO
O
O
2



CA 02476824 2004-08-19
WO 03/070678 PCT/US03/03082
The present invention relates to a process for producing an intermediate that
is used to
make a dihydropyridine potassium channel opener.
Detailed Description of the Invention
The present invention relates to an efficient synthesis of 4-fluoro-3-iodo-
benzaldehyde by
iodinating 4-fluoro-benzaldehyde. 4-Fluoro-3-iodo-benzaldehyde is a key
intermediate in the
manufacture of the potassium channel opener, 5-(4-fluoro-3-iodophenyl)-5,10
dihydro-1H,3H-
dipyrano[3,4-b:4,3-a]pyridine-4,6(7H,9H) dione.
The present invention relates to an improved process for iodinating
benzaldehydes. As
shown in Scheme III, the improved process allows for a one- step procedure for
synthesizing 4-
fluoro-3-iodo-benzaldehyde. 4-Fluoro-3-iodobenzaldehyde is synthesized by
combining 4-
fluorobenzaldehyde and N-iodosuccinimide in an acid medium. Preferably, the 4-
Fluoro-3-
iodobenzaldehyde and N-iodosuccinimide are in a 1:1.2 equivalents ratio
respectively.
Suitable acids for use in the present invention include organic acids and
inorganic acids.
An example of organic acids suitable for use in the present invention
includes, but is not
intended to be limited to, trifluoromethanesulfonic acid.
Inorganic acids are suitable for use in the present invention as well.
Inorganic acids
suitable for use in the present invention include, but is not intended to be
limited to, nitric acid,
sulfuric acid, and hydrochloride acid.
The inorganic acid may be used in combination with acetic acid as well. Acetic
acid is
used for solubility purposes. A strong inorganic acid/acetic acid combination
is suitable for use
in the present invention. Preferably, the inorganic acid/acetic acid
combination is in a 1:1 ratio.
Scheme III
F F
I
( N-Iodosuccinimide
Acid
10 CHO 6 CHO
3



CA 02476824 2004-08-19
WO 03/070678 PCT/US03/03082
Example 1
4-Fluorobenzaldehyde (40.0 g), N-iodosuccinimide (87.1 g) and acetic acid (80
mL) were
added to a flask. Sulfuric acid (80 mL) is added slowly, maintaining the
temperature below
40°C. The resulting mixture was stirred for 2.5 h at 40 °C and
then after cooling to 10 °C, water
(400 mL) was added, maintaining the temperature below 35 °C. After
stirnng for 30 min at
room temperature the slurry was filtered and the resulting solid washed with
water (80 mL). The
wetcake was dissolved in 380 g ethyl acetate / heptane (1:1 v/v containing 250
ppm BHT) and
the solution was washed with 10% aqueous sodium thiosulfate (204 g), then with
10% aqueous
sodium carbonate (214 g), followed by 200 g water.
1 S The solution was concentrated to approximately 40 mL, and 148 g heptane
(containing
BHT) was added. This was distilled again to approximately 40 mL, to remove all
of the ethyl
acetate. Heptane (265 g) was added and the resulting mixture heated to 55
°C to dissolve the
solids The solution was cooled to approximately 40 °C and seed crystals
were added. Cooling
was continued until the temperature reached 5 °C and then the slurry
was filtered. After washing
the wetcake with cold heptane, the product was dried in a vacuum oven at 40
°C.
4

Representative Drawing

Sorry, the representative drawing for patent document number 2476824 was not found.

Administrative Status

For a clearer understanding of the status of the application/patent presented on this page, the site Disclaimer , as well as the definitions for Patent , Administrative Status , Maintenance Fee  and Payment History  should be consulted.

Administrative Status

Title Date
Forecasted Issue Date Unavailable
(86) PCT Filing Date 2003-02-03
(87) PCT Publication Date 2003-08-28
(85) National Entry 2004-08-19
Dead Application 2007-02-05

Abandonment History

Abandonment Date Reason Reinstatement Date
2006-02-03 FAILURE TO PAY APPLICATION MAINTENANCE FEE

Payment History

Fee Type Anniversary Year Due Date Amount Paid Paid Date
Registration of a document - section 124 $100.00 2004-08-19
Application Fee $400.00 2004-08-19
Maintenance Fee - Application - New Act 2 2005-02-03 $100.00 2005-01-11
Owners on Record

Note: Records showing the ownership history in alphabetical order.

Current Owners on Record
ABBOTT LABORATORIES
Past Owners on Record
CHANG, SOU-JEN
WAYNE, GREGORY S.
WITTENBERGER, STEVEN J.
Past Owners that do not appear in the "Owners on Record" listing will appear in other documentation within the application.
Documents

To view selected files, please enter reCAPTCHA code :



To view images, click a link in the Document Description column. To download the documents, select one or more checkboxes in the first column and then click the "Download Selected in PDF format (Zip Archive)" or the "Download Selected as Single PDF" button.

List of published and non-published patent-specific documents on the CPD .

If you have any difficulty accessing content, you can call the Client Service Centre at 1-866-997-1936 or send them an e-mail at CIPO Client Service Centre.


Document
Description 
Date
(yyyy-mm-dd) 
Number of pages   Size of Image (KB) 
Claims 2004-08-19 1 16
Description 2004-08-19 4 131
Abstract 2004-08-19 1 36
Cover Page 2004-10-25 1 23
PCT 2004-08-19 4 108
Assignment 2004-08-19 8 294
Fees 2005-01-11 1 31
PCT 2007-03-28 3 153